Alchemab

News

Alchemab's chief executive, Jane Osbourn

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

R&D

Turning drug development on its head

In episode 98 of the pharmaphorum podcast , host Jonah Comstock and Alchemab CEO Young Kwon discuss innovative new routes to drug discovery

News

UK says it has hit target on commercial trial set-up times

The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in industry-backed studies.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks